While it is not FDA-approved, clinicians and patients alike are watching it closely because it represents a new direction in peptide therapy for weight loss where its triple-agonist mechanism is something that many did not expect
The drug was removed from the Drug Shortage List in February 2025 after being added to the list in August 2022
GLP-1RAs may benefit glaucoma by reducing aqueous humour production
This summer, wanting to shed fat and gain muscle, he sought out retatrutide, a next-generation GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor agonista triple agonist targeting appetite, blood sugar, and metabolism
Please email [email protected] within 24 hours of your completed provider review
Muscle preservation is especially important for women